Document Detail

Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.
MedLine Citation:
PMID:  20555330     Owner:  NLM     Status:  MEDLINE    
Telmisartan, a selective antagonist for angiotensin type1 receptor and a partial agonist for peroxisome proliferator-activated receptor-gamma, decreases blood pressure and has been shown to improve glucose and lipid metabolism, suggesting potential cardiovascular protective effects. In this study, we investigated whether long-term treatment with telmisartan improved endothelial function in 35 hypertensive patients with type 2 diabetes mellitus (T2DM). Office and home early morning blood pressure levels and flow-mediated vasodilation (FMD) were evaluated before and after 12 months of treatment with telmisartan. Blood samples were also obtained for measurement of several biochemical parameters and of adiponectin (AN) and highly sensitive C-reactive protein (hs-CRP) before and after treatment. After 12 months of treatment, office and morning blood pressure levels had significantly decreased, and levels of plasma glucose, glycosylated hemoglobin, total cholesterol, triglyceride and low-density lipoprotein cholesterol had also significantly decreased. Plasma AN and high-density lipoprotein cholesterol levels increased, but hs-CRP levels decreased. Furthermore, FMD significantly increased; changes in percent FMD showed a significant negative correlation with changes in systolic and diastolic blood pressure and a significant positive correlation with changes in AN. Stepwise multivariate regression analysis revealed that changes in plasma AN and office systolic blood pressure were both independent determinants for endothelial function after telmisartan treatment. In conclusion, this study shows that long-term treatment with telmisartan improves not only blood pressure and glucose and lipid metabolism but also endothelial function in hypertensive patients with T2DM, possibly by increased circulating AN and decreased blood pressure.
Takehiko Wago; Takanobu Yoshimoto; Itaru Akaza; Kyoichiro Tsuchiya; Hajime Izumiyama; Masaru Doi; Yukio Hirata
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-17
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  33     ISSN:  1348-4214     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-05     Completed Date:  2010-11-16     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  796-801     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adiponectin / blood
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Benzimidazoles / administration & dosage*
Benzoates / administration & dosage*
Blood Glucose / drug effects
Blood Pressure / drug effects
C-Reactive Protein / metabolism
Diabetes Mellitus, Type 2 / complications,  drug therapy*,  metabolism
Endothelium, Vascular / drug effects*,  physiology
Hypertension / complications,  drug therapy*,  metabolism
Lipids / blood
Middle Aged
Prospective Studies
Treatment Outcome
Vasodilation / drug effects
Reg. No./Substance:
0/ADIPOQ protein, human; 0/Adiponectin; 0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Blood Glucose; 0/Lipids; 9007-41-4/C-Reactive Protein; U5SYW473RQ/telmisartan
Comment In:
Hypertens Res. 2010 Aug;33(8):780-1   [PMID:  20555332 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of angiotensin II receptor blockers on insulin resistance.
Next Document:  Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(...